

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference CHIR-1-20669	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/US03/06742	International filing date (<i>day/month/year</i>) 03 March 2003 (03.03.2003)	(Earliest) Priority Date (<i>day/month/year</i>)
Applicant CHIRON CORPORATION		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 4 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the Report

a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☐ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (See Box II).

4. With regard to the title,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

5. With regard to the abstract,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No. _____



as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.



None of the figures

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/06742

A. CLASSIFICATION OF SUBJECT MATTER																										
IPC(7) : A61K 38/16																										
US CL : 514/12																										
According to International Patent Classification (IPC) or to both national classification and IPC																										
B. FIELDS SEARCHED																										
Minimum documentation searched (classification system followed by classification symbols)																										
U.S. : 514/12																										
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																										
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)																										
Please See Continuation Sheet																										
C. DOCUMENTS CONSIDERED TO BE RELEVANT																										
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																								
X --- Y	EP 1 136 493 A1 (SANOFI-SYNTHELABO) 26 September 2001, (26.09.2001) see abstract, see page 2, lines 10-38.	1-4, 11, 17, 36, 48-50, 54 ----- 5-9, 12-16, 18-35, 37-47, 51-53, 55-56																								
X --- Y	US 2002/0147146 A1 (ELDAR-FINKELMAN, HAGIT) 10 October 2002 (10.10.2002), see abstract.	1, 17, 36, 48-50, 54 ----- 2-16, 18-35, 37-47, 51-53, 55-56																								
X --- Y	WO 01/70727 A1 (SANOFI-SYNTHELABO) 27 September 2001 (27.09.2001) see abstract, see page 1, line 14 to page 2, line 19.	1, 17, 36, 48-50, 54 ----- 2-16, 18-35, 37-47, 51-53, 55-56																								
X --- Y	US 6,417,185 B1 (GOFF et al.) 09 July 2002 (09.07.2002) see abstract, column 33, line 50 to column 34, line 58.	1, 17, 36, 48-50, 54 ----- 2-16, 18-35, 37-47, 51-53, 55-56																								
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																										
<table border="0"> <tr> <td colspan="2">* Special categories of cited documents:</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"E"</td> <td>earlier application or patent published on or after the international filing date</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family	"O"	document referring to an oral disclosure, use, exhibition or other means			"P"	document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																							
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																							
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																							
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family																							
"O"	document referring to an oral disclosure, use, exhibition or other means																									
"P"	document published prior to the international filing date but later than the priority date claimed																									
Date of the actual completion of the international search		Date of mailing of the international search report																								
30 June 2003 (30.06.2003)		22 JUL 2003																								
Name and mailing address of the ISA/US		Authorized officer																								
Mail Stop PCT, Attn: ISA/US		Donna Jagoe																								
Commissioner for Patents																										
P.O. Box 1450																										
Alexandria, Virginia 22313-1450		Telephone No. (703) 308-1235																								
Facsimile No. (703)305-3230																										

Form PCT/ISA/210 (second sheet) (July 1998)

Best Available Copy

INTERNATIONAL SEARCH REPORT

PCT/US03/06742

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2001/0044436 A1 (NUSS et al.) 22 November 2001(22.11.2001), see entire document.	1-56

INTERNATIONAL SEARCH REPORT

PCT/US03/0

Continuation of B. FIELDS SEARCHED Item 3:

WEST 2.1, STN file medicine search terms, glycogen synthase inhibitor or antagonist, tau protein kinase inhibitor or TPK I or FA kinase inhibitor or kinase FA inhibitor, anticoagulant or thrombolytic or fibrinolytic or neuroprotective or antiplatelet, molecular weight or MW, log p, ischemia, stroke, cardiovascular cerebrovascular